Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Peter Hartung

Showing results (1-10 of 707) with videos related to

Pageof 71
Sort By:
Journal of Neurology|September 20, 2008
Advances in the understanding of the mechanism of action of IVIgHans-Peter Hartung
Expert Review of Neurotherapeutics|April 19, 2012
Advances in the management of multiple sclerosis-related spasticityHans-Peter Hartung
The Lancet. Neurology|June 1, 2014
Interferon β-1a for multiple sclerosis: old drug, new clothesHans-Peter Hartung
Neurology(R) Neuroimmunology & Neuroinflammation|June 7, 2020
Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MSHans-Peter Hartung,
Expert Opinion on Pharmacotherapy|February 25, 2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosisHans-Peter Hartung
The Lancet. Neurology|December 17, 2008
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumabHans-Peter Hartung
Annals of Neurology|April 19, 2021
Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-MakingHans-Peter Hartung
Annals of Neurology|October 20, 2021
Correction to "Hartung H-P. Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making."Hans-Peter Hartung
Current Opinion in Neurology|June 8, 2022
Editorial: Advances in Multiple SclerosisHans-Peter Hartung
Journal of Neurology|September 20, 2005
Early treatment and dose optimisation BENEFIT and BEYONDHans-Peter Hartung
Pageof 71

Showing results (1-10 of 707) with videos related to

Sort By:
Pageof 71
Journal of Neurology|September 20, 2008
Advances in the understanding of the mechanism of action of IVIgHans-Peter Hartung
Expert Review of Neurotherapeutics|April 19, 2012
Advances in the management of multiple sclerosis-related spasticityHans-Peter Hartung
The Lancet. Neurology|June 1, 2014
Interferon β-1a for multiple sclerosis: old drug, new clothesHans-Peter Hartung
Neurology(R) Neuroimmunology & Neuroinflammation|June 7, 2020
Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MSHans-Peter Hartung,
Expert Opinion on Pharmacotherapy|February 25, 2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosisHans-Peter Hartung
The Lancet. Neurology|December 17, 2008
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumabHans-Peter Hartung
Annals of Neurology|April 19, 2021
Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-MakingHans-Peter Hartung
Annals of Neurology|October 20, 2021
Correction to "Hartung H-P. Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making."Hans-Peter Hartung
Current Opinion in Neurology|June 8, 2022
Editorial: Advances in Multiple SclerosisHans-Peter Hartung
Journal of Neurology|September 20, 2005
Early treatment and dose optimisation BENEFIT and BEYONDHans-Peter Hartung
Pageof 71